Charles Alexander Glass

Tega Therapeutics, Inc.

$2,637,213

Attributed

$7,488,203

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.2M · FY2015–25

$5M$3.8M$2.5M$1.3M$0

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$7,488,203 · 6

By mechanism

U44$5,612,276 · 1

R43$1,875,927 · 5

Top collaborators

Most similar at Tega Therapeutics, Inc.

Same institution · by research overlap

Bryan Edward Thacker$160,933

Others in their field

Top investigators on “Production”

Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
Bambra Strokes · Ppd Development Lp$526,656,217
Richard A Gibbs · Baylor College Of Medicine$521,766,399
Tracy L Nolen · Research Triangle Institute$451,761,218
Sonia M Thomas · Research Triangle Institute$451,761,218
David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970

Research focus

ProductionDoseEnzymesLifeCessation Of LifeBlood - Brain Barrier AnatomyEnzyme ActivitySymptomsSuccessMutationRecombinantsBrainEffective TherapyProteinsQuality Of LifeIn VivoClinical TrialsHeparitin SulfateNerve DegenerationBaseCellsCerebrospinal FluidAnimalsAnimal Model

Grant awards (7)

Title: New Clinical Biomarkers for GM1 Gamgliosidosis$500,000

R43 · FY2025 · NS

Testing Novel Advancements to Recombinant Heparin Production$355,222

R43 · FY2024 · HL · contact PI

Title: Development and Validation of Therapy for GM1 Gangliosidosis$461,701

R43 · FY2023 · NS

Development and Validation of Therapy for Mucopolysaccharidosis III$2,435,870

U44 · FY2022 · NS

Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad$321,866

R43 · FY2022 · HL · contact PI

Development and validation of therapy for mucopolysaccharidosis III$3,176,406

U44 · FY2018 · NS

Intranasal Sulfamidase Delivery to the Brain$237,138

R43 · FY2015 · NS · contact PI